{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-26-044263","form_type":"8-K","ticker":"SION","cik":"0002036042","company_name":"Sionna Therapeutics, Inc.","filed_at":"2026-06-18T20:05:31+00:00","discovered_at":"2026-06-18T20:07:00.329497+00:00","generated_at":"2026-06-18T20:12:19.347229+00:00","sec_items":["5.07"],"event_type":"other","sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"confidence":"high","headline":"Sionna Therapeutics annual meeting results: all director nominees elected, auditor ratified","bullets":["Four Class II directors elected: H. Edward Fleming, Marcella Kuhlman Ruddy, Peter A. Thompson, Joanne Louise Viney.","Ratification of Deloitte & Touche LLP as independent auditor for FY 2026 approved with 43,291,215 votes for.","Meeting held June 17, 2026; 45,142,330 shares outstanding as of record date April 21, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-26-044263","json":"https://secwatch.observer/filing/0001628280-26-044263.json","markdown":"https://secwatch.observer/filing/0001628280-26-044263.md","text":"https://secwatch.observer/filing/0001628280-26-044263.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026044263/0001628280-26-044263-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026044263/sion-20260617.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T20:12:19.347229+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"9a75113251a6bc32f188241376edf7f01fc751eb","claim":"Sionna Therapeutics, Inc. shareholders approved Election of four Class II directors at the 2026-06-17 meeting.","evidence_excerpt":"1. To elect four nominees as Class II directors: H. Edward Fleming, Jr., M.D., Marcella Kuhlman Ruddy, M.D., Peter A. Thompson, M.D., and Joanne Louise Viney, Ph.D., each to hold office until the Company's Annual Meeting of Stockholders in 2029.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026044263/0001628280-26-044263-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"director election"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"},{"claim_id":"e9f6c6f330e05b8e686b4cf0e77eed23070aa06e","claim":"Sionna Therapeutics, Inc. shareholders approved Ratification of appointment of Deloitte & Touche LLP as independent registered public accounting firm for fiscal year ending December 31, 2026 at the 2026-06-17 meeting.","evidence_excerpt":"2. To ratify the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026.","evidence_source":"SEC 8-K Item 5.07","evidence_url":"https://www.sec.gov/Archives/edgar/data/2036042/000162828026044263/0001628280-26-044263-index.htm","confidence":0.9,"family_label":"Shareholder Votes","details":[{"label":"Proposal","value":"auditor ratification"},{"label":"Outcome","value":"passed"},{"label":"Meeting","value":"2026-06-17"}],"fact_type":"shareholder_vote"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}